NATHANIEL METHOT: Open Payments
NPI 1225422140 · TUOLUMNE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$334 in 15 payments from 11 companies in 2025. Trend: 2023 $484 · 2024 $230 · 2025 $334
Food & beverage: $334
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $85 |
| Corcept Therapeutics | 3 | $52 |
| Vanda Pharmaceuticals Inc. | 1 | $38 |
| Aimmune Therapeutics, Inc. | 1 | $29 |
| ABBVIE INC. | 1 | $24 |
| Gilead Sciences, Inc. | 1 | $22 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $20 |
| AstraZeneca Pharmaceuticals LP | 1 | $19 |
| Madrigal Pharmaceuticals | 1 | $19 |
| Amgen Inc. | 1 | $14 |
Products named: Korlym, HETLIOZ, Rybelsus, VOWST, Ozempic, Wegovy, QULIPTA, Kerendia.
Industry payments across CA — which companies pay providers there.
